CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE The LUMIERE Study
CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE The LUMIERE Study
复制标题
DOI：
10.1097/iae.0b013e31827b6324
复制
发表时间：
2013-03-01
影响因子：
3.3
通讯作者：
Schneider, Veronique
中科院分区：
文献类型：
--
作者：
Cohen, Salomon Y.;Mimoun, Gerard;Schneider, Veronique
目的：调查法国日常临床实践中推荐的玻璃体内雷珠单抗治疗方案的依从性，并参考结果。方法：对接受雷珠单抗治疗的黄斑中心凹下湿性年龄相关性黄斑变性患者进行回顾性、描述性、观察性研究。研究期间的所有历史数据，包括人口统计、治疗、疾病细节和视力测量（基线、第 3 个月和第 12 个月），均在治疗开始后至少 12 个月进行回顾性记录。 结果：在 16 名眼科医生随访的 551 名患者中，12 个月的玻璃体内雷珠单抗治疗使平均视力提高了 3.2 +/- 14.8。研究等效字母。不到 40% 的患者接受了最初 3 个月注射的推荐治疗。超过 50% 的患者在诊断和治疗之间必须等待 8 天以上。在第 3 个月，接受推荐的诱导治疗并迅速开始治疗的患者的视力增益更高。第 12 个月时，诱导相关效应已基本消失，但治疗时间效应仍然存在。患者平均注射 5.1 次（诱导期为 2.6 次）。没有按照指南中的规定每月对患者进行监测。结论：尽管结果平庸，反映出对建议的依从性较差，但有证据表明实践正在改善。视网膜 33:474-481, 2013
Purpose: To survey compliance with recommended intravitreal ranibizumab treatment protocols in daily clinical practice in France, with reference to outcomes.Methods: A retrospective, descriptive, observational study in patients with subfoveal wet age-related macular degeneration treated with ranibizumab. All historical data for the study period, including demographic, treatment, and disease details and visual acuity measurements (baseline, Month 3, and Month 12), were recorded retrospectively at least 12 months after the beginning of treatment.Results: In 551 patients followed by 16 ophthalmologists, 12 months of intravitreal ranibizumab treatment induced a mean visual acuity gain of 3.2 +/- 14.8 Early Treatment Diabetic Retinopathy Study-equivalent letters. Fewer than 40% of patients received the recommended treatment of initial 3 monthly injections. More than 50% had to wait >8 days between diagnosis and treatment. At Month 3, visual acuity gain was greater in patients who had received recommended induction and in whom treatment was initiated quickly. At Month 12, the induction-related effect had largely disappeared but the time-to-treatment effect persisted. Patients had an average of 5.1 injections (2.6 during induction period). No patients were monitored monthly as stipulated in the guidelines.Conclusion: Although poor compliance with recommendations has been reflected in mediocre outcomes, there is evidence that practice is improving. RETINA 33:474-481, 2013